Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Roche and its subsidiary TIB Molbiol have developed three different LightMix Modular Virus kits for the detection of the virus
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Formula attenuates 99% of 365 coronaviruses in computer models
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
Subscribe To Our Newsletter & Stay Updated
